<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lodlow, Karinne</style></author><author><style face="normal" font="default" size="100%">Bowman, Diana M.</style></author><author><style face="normal" font="default" size="100%">Kirk, Dwayne, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hitting the mark or falling short with nanotechnology regulation?</style></title><secondary-title><style face="normal" font="default" size="100%">Trends in Biotechnology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">09/2009</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/19740561</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">615-620</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Drawing on the history of the history of the regulation of genetic modification, the authors predict that nanotechnology will go through a similar process of inappropriate regulation. They argue that the timing and type of regulation adopted for nanotechnology will be crucial in deciding its commercial success. Full abstract available in PubMed.</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue></record></records></xml>